Establishing Normative Values for Event Related Potentials (ERPs) and Quantitative EEG (QEEG) in Adult, Healthy Volunteers

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

Many scientific papers have reported that ERP and QEEG biomarkers can be useful in the evaluation of neurological and psychiatric disorders. A study previously conducted with the COGNISION® system has shown how data collected with the system could help detect cognitive deficits in elderly individuals with probable early Alzheimer's disease (Cecchi et al., 2015). Furthermore, normative ranges for ERP and QEEG parameters are sensitive to subject age (see for example van Dinteren et al., 2014). This study will use advanced EEG techniques to measure brain function among healthy adults ages 20 through 59 to use as reference data to compare against individuals that suffer from neurological and psychiatric disorders. QEEG and ERP parameters from the current study will compliment previously collected normative data in healthy subjects 60 years of age and older (Cecchi et al., 2015).

Eligibility
Participation Requirements
Sex: All
Minimum Age: 20
Maximum Age: 59
Healthy Volunteers: t
View:

• Male and female volunteers 20-59 years of age, inclusive.

• Willingness and ability to provide 1 form of identification with picture.

• Willingness and ability to provide to understand the requirements of the study, provide written informed consent, and abide by the study procedures.

• Fluency in English, even if English is not the primary language.

• Ability to tolerate the electrode cap for the duration of the testing session.

• Subject has not been enrolled or actively participating in another clinical study 4 weeks prior to testing.

Locations
United States
Kentucky
Cognision
RECRUITING
Louisville
Contact Information
Primary
Vickie Tang
vtang@cognision.com
(502) 294-5109
Time Frame
Start Date: 2023-05-22
Estimated Completion Date: 2024-09-30
Participants
Target number of participants: 80
Treatments
Cohort 1 (n=10)
Gender: Male Age: 20-29
Cohort 2 (n=10)
Gender: Female Age: 20-29
Cohort 3 (n=10)
Gender: Male Age: 30-39
Cohort 4 (n=10)
Gender: Female Age: 30-39
Cohort 5 (n=10)
Gender: Male Age: 40-49
Cohort 6 (n=10)
Gender: Female Age: 40-49
Cohort 7 (n=10)
Gender: Male Age: 50-59
Cohort 8 (n=10)
Gender: Female Age: 50-59
Related Therapeutic Areas
Sponsors
Leads: Neuronetrix, Inc.

This content was sourced from clinicaltrials.gov